摘要
目的:根据血栓的形成机制,对凝血酶的直接抑制而成为对抗静脉血栓和心血管事件的一线抉择,受到临床和患者的关注。本文总结直接凝血酶抑制剂的研究进展与临床评价。方法:收集国内外相关文献进行评价。结果与结论:在大量临床研究中,直接凝血酶抑制剂显示出良好的效果。相对华法林而言,其更特异地抑制血栓的形成,抗凝作用快,抗凝效果与剂量有良好的相关性,不与血浆蛋白结合,无需监测国际标准化比率,标志一个新颖抗凝治疗里程的开始。
OBJECTIVE： Based on thrombogenesis mechanism that because of the direct inhibition on thrombin, direct thrombin inhibitor has become the first choice against phlebothrombosis and cardiovascular events and it has gained the attention of both clinicians and patients. This paper summarized the research progress of and clinical evaluation on direct thrombin inhibitor. METHODS： The pertinent literature both at home and abroad was retrieved and evaluated. RESULTS ＆ CONCLUSION： Numerous clinical trials demonstrated the satisfactory efficacy of the direct thrombin inhibitor. As compared with warfarin, the direct thrombin inhibitor could more specifically inhibit thrombogenesis with fast anticoagulation action, good correlation between antieoagulative efficacy and doses yet without binding with plasma protein and without need for international normalized ratio, which indicates a start of novel antieoagulation therapy.
出处
《中国医院用药评价与分析》
2013年第7期586-590,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
